Compare First Horizon Corporation Common Stock (FHN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Horizon Corporation Common Stock vs 10X Genomics Inc — how do they compare? First Horizon Corporation Common Stock trades at $22.63 (market cap $10.74B), while 10X Genomics Inc trades at $70.5 (market cap $9.53B). The key difference: First Horizon Corporation Common Stock and 10X Genomics Inc are close in size by market cap, and First Horizon Corporation Common Stock pays a 3% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.
| FHN | TXG | |
|---|---|---|
Market Cap | $10.74B | $9.53B |
Volume | 11,773,440 | 4,138,224 |
Sector | Financials | Health |
52-Week High | $26.23 | $97.74 |
52-Week Low | $19.94 | $11.83 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $14.03B | $9.05B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.
The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.
TXG (10x Genomics) trades at $71.79, down 4.52% on the day, amid a bearish technical signal. The company shows improving fundamentals with a significant reduction in net losses (-$43.54M in 2025 vs. -$183M in 2024) and positive operating cash flow of $136.05M. Recent news highlights strong demand for its new Atera spatial biology platform and a patent victory. However, valuation metrics remain elevated with a P/S of 14.86 and EV/EBITDA of 230.71.
The outlook is cautiously optimistic. Analyst consensus is mixed with a $83.30 price target implying 16% upside, but execution on Atera commercialization and sustained margin improvement are critical. Key risks include high valuation, competitive pressures, and reliance on instrument sales growth. The stock offers growth exposure to spatial biology but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Horizon Corporation Common Stock
First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.
Read more on FHN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
